⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ANAB News
AnaptysBio, Inc. Common Stock
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
prnewswire.com
VNDA
ANAB
Anaptys Announces Participation in December Investor Conferences
globenewswire.com
ANAB
Companies Prioritize Revenue Performance with AI, ISG Says
businesswire.com
III
ANAB
XACT
ORCL
CRM
SAP
WDAY
ACN
IBM
MSFT
GOOG
AMZN
ADBE
NOW
INTU
PAYX
FIS
PAYC
SNOW
DDOG
MDB
PLTR
AI
SMCI
NVDA
AMD
INTC
QCOM
META
NFLX
CMCSA
VZ
T
CSCO
HPQ
DELL
PANW
CRWD
FTNT
ZBRA
CDNS
SNPS
MRVL
NXPI
MU
WDC
AMAT
LRCX
KLAC
ASML
ADI
TXN
ON
MPWR
AEHR
ARM
AVGO
AMGN
GILD
BMY
PFE
MRK
JNJ
LLY
ABBV
MDT
ISRG
BIIB
REGN
AZN
NVS
RHHBY
XOM
CVX
SHEL
TCEHY
BABA
JD
PDD
NTES
BIDU
IQ
VIPS
YY
BEKE
NIO
LI
XPEV
RIVN
LCID
TSLA
GM
F
STLA
TM
HMC
VWAGY
BMW
DAI
GE
HON
BA
LMT
RTX
GD
NOC
CAT
DE
AGCO
CNH
J
CHTR
CMCSK
TMUS
ATVI
EA
TTWO
DIS
FOX
PARA
WBD
LYV
AMC
NCLH
CCL
RCL
DAL
UAL
AAL
LUV
JBLU
ALK
MAR
HLT
IHG
WYNN
LVS
MGM
CHKP
Zscaler
AKR
VAR
NICE
BOARD
FORM
PIG
INFSPM
PERF
FULL
CAP
EVER
JED
OPT
XOXO
ELEV
Anaptys Announces $100 Million Stock Repurchase Plan
globenewswire.com
ANAB
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
globenewswire.com
ANAB
GSK
Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis
globenewswire.com
ANAB
Anaptys Announces Participation in November Investor Conferences
globenewswire.com
ANAB
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
globenewswire.com
ANAB
Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation
globenewswire.com
ANAB
Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025
globenewswire.com
ANAB